Nicox SA, an international ophthalmology company, announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a New Drug Application for approval to commercialize ZERVIATE®, 0.24%, in China, for ocular itching associated with allergic conjunctivitis.
